Mydriasert (Phenylephrine Hydrochloride, Tropicamide)

Phenylephrine hydrochloride stimulates α1‑adrenergic receptors in the dilator pupillae muscle, causing it to contract and widen the pupil. Tropicamide blocks muscarinic receptors in the iris sphincter, preventing constriction. Together they produce rapid and sustained pupil dilation and cycloplegia.

The specific dosing regimen for Mydriasert is determined by the prescribing eye care professional based on the patient’s age, clinical indication, and response. Typically, one drop is instilled in the conjunctival sac of each eye, but exact frequency and concentration are set by the clinician.

Safety data for Mydriasert in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss alternatives when appropriate.

To request Mydriasert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mydriaset combines phenylephrine, an α1‑agonist, with tropicamide, an antimuscarinic, offering both rapid dilation and cycloplegia. Compared with agents like atropine (long‑acting) or cyclopentolate (moderate duration), Mydriaset provides a quicker onset and shorter duration, making it suitable for routine diagnostic procedures.

Mydriasert should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct sunlight, moisture, and freezing. Keep the vial tightly sealed when not in use to maintain sterility.

Mydriasert is applied topically to the eye. The prescriber typically instructs the patient to instill one drop into the conjunctival sac of each eye, avoiding contact with the eyelid or lashes. The drop should be administered using a clean fingertip or applicator, and the patient should blink gently to spread the solution.

The most serious risks include acute angle‑closure glaucoma, severe allergic reactions such as anaphylaxis, and systemic hypertension or cardiovascular events due to phenylephrine absorption. Patients should be monitored for sudden eye pain, visual changes, or systemic symptoms and seek immediate medical attention if they occur.

Mydriasert is contraindicated in individuals with known hypersensitivity to phenylephrine, tropicamide, or any formulation components. It should also be avoided in patients with narrow‑angle or uncontrolled glaucoma, severe cardiovascular disease, or those taking systemic α‑adrenergic agonists without medical supervision.